GPR52 Antagonist Reduces Huntingtin Levels and Ameliorates Huntington’s Disease-Related Phenotypes
作者:Congcong Wang、Yu-Fang Zhang、Shimeng Guo、Quan Zhao、Yanping Zeng、Zhicheng Xie、Xin Xie、Boxun Lu、Youhong Hu
DOI:10.1021/acs.jmedchem.0c01133
日期:2021.1.28
studies showed that Comp-43 reduces mHTT levels by targeting GPR52 and promotes survival of mouse primary striatal neurons. Moreover, in vivo study showed that Comp-43 not only reduces mHTT levels but also rescues HD-related phenotypes in HdhQ140 mice. Taken together, our study confirms that inhibition of GPR52 is a promising strategy for HD therapy, and the GPR52 antagonist Comp-43 might serve as a lead
GPR52是一种孤儿G蛋白偶联受体(GPCR),最近被认为是亨廷顿氏病(HD)(一种无法治愈的单基因神经退行性疾病)的潜在药物靶标。在这项研究中,我们发现GPR52的纹状体敲低可降低成年HdhQ140小鼠的mHTT水平,从而将GPR52确认为HD靶标。此外,通过结构-活性关系(SAR)研究,我们发现了一种高效且特异的GPR52拮抗剂Comp- 43,IC 50值为0.63μM 。进一步的研究表明,Comp- 43通过靶向GPR52降低mHTT水平,并促进了小鼠原代纹状体神经元的存活。此外,体内研究表明Comp- 43不仅降低了mHTT水平,而且还挽救了HdhQ140小鼠的HD相关表型。两者合计,我们的研究证实,抑制GPR52是HD治疗的一种有前途的策略,而GPR52拮抗剂Comp- 43可能充当进一步研究的先导化合物。